Short Interest in BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Drops By 77.3%

BriaCell Therapeutics Corp. (NASDAQ:BCTXWGet Free Report) was the target of a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 2,900 shares, a decline of 77.3% from the November 30th total of 12,800 shares. Based on an average daily volume of 158,000 shares, the short-interest ratio is currently 0.0 days.

BriaCell Therapeutics Stock Performance

BCTXW stock traded down $0.01 during midday trading on Friday, hitting $0.28. The company had a trading volume of 53,515 shares, compared to its average volume of 86,532. BriaCell Therapeutics has a 52 week low of $0.11 and a 52 week high of $2.60. The stock’s 50 day moving average price is $0.34 and its 200 day moving average price is $0.28.

BriaCell Therapeutics Company Profile

(Get Free Report)

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.

See Also

Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.